Scinai Completes Recipharm Israel Acquisition, Forms Strategic Commercial Collaboration
SCNI sits 24% above its 52-week low of $0.613 on light trading volume (0.3× avg).
Summary
Scinai Immunotherapeutics announced the completion of its acquisition of Recipharm Israel Ltd. and a strategic commercial collaboration with Recipharm, significantly expanding its CDMO capabilities and market reach.
Key Events · M&A and Partnerships · SCNI
-
Acquisition of Recipharm Israel Ltd. Completed
Scinai acquired 100% of Recipharm Israel Ltd., which operates a cGMP manufacturing site in Yavne, Israel, providing early chemistry development and small-scale API manufacturing for clinical programs. This acquisition expands Scinai's manufacturing footprint and capabilities.
-
Strategic Commercial Collaboration with Recipharm Established
Scinai and Recipharm entered a long-term agreement where Scinai will be a preferred partner for early-stage development, and Recipharm for late-stage clinical and commercial manufacturing. The collaboration includes mutual client referrals and shared economics as programs advance.
-
Expanded CDMO Offering and Market Positioning
The transactions significantly strengthen Scinai's CDMO platform, creating a differentiated, end-to-end development and manufacturing offering. This allows Scinai to support clients from early development through commercialization, addressing a common industry challenge for smaller CDMOs.
Analysis · SCNI · Life Sciences
Scinai Immunotherapeutics has significantly expanded its contract development and manufacturing organization (CDMO) capabilities and market reach through the acquisition of Recipharm Israel Ltd. and a strategic commercial collaboration with Recipharm. This move creates a differentiated, end-to-end offering for clients, spanning early development through late-stage clinical and commercial supply. The collaboration is designed to streamline client transitions to Recipharm's global network and allows Scinai to participate economically in the long-term success of client programs, enhancing its competitive positioning in the CDMO market.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1838 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCNI was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $635K. The 52-week trading range was $0.61 to $6.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.